Gene fusion is involved in the development of various types of malignancies. Recent advances in sequencing technology have facilitated identification of gene fusions and have stimulated the research of this field in cancer. In the present study, we performed next-generation transcriptome sequencing in order to discover novel gene fusions in gastric cancer. A total of 282 fusion transcript candidates were detected from 12 gastric cancer cell lines by bioinformatic filtering. Among the candidates, we have validated 19 fusion transcripts, which are 7 inter-chromosomal and 12 intra-chromosomal fusions. A novel DUS4L-BCAP29 fusion transcript was found in 2 out of 12 cell lines and 10 out of 13 gastric cancer tissues. Knockdown of DUS4L-BCAP29 transcript using siRNA inhibited cell proliferation. Soft agar assay further confirmed that this novel fusion transcript has tumorigenic potential. We also identified that microRNA-coding gene PVT1, which is amplified in double minute chromosomes in SNU-16 cells, is recurrently involved in gene fusion. PVT1 produced six different fusion transcripts involving four different genes as fusion partners. Our findings provide better insight into transcriptional and genetic alterations of gastric cancer: namely, the tumorigenic effects of transcriptional read-through and a candidate region for genetic instability.
INTRODUCTION
Gene fusion is one of the common oncogenic activation mechanisms involved in the development of various types of malignancies including leukaemia, lymphoma, sarcoma and prostate cancer. 1 More importantly, gene fusions can produce important druggable targets, which make detection of gene fusion as an essential part of diagnosis and treatment strategy for some malignancies. Representative example is imatinib targeting BCR-ABL tyrosine kinase, which has entirely changed treatment paradigm of chronic myelogenous leukaemia. 2 Recent success of crizotinib in nonsmall cell lung cancer harbouring EML4-ALK fusion has further underscored the importance of identifying novel gene fusions and effective targeted agents. 3, 4 Although other methods for detecting genetic alterations have been used, it was the advent of next-generation sequencing that stimulated the fusion gene research in epithelial cancers. Transcriptome sequencing has been the main contributor to fusion gene studies, for example, on breast, 5, 6 prostate 7, 8 and gastric cancers. 9 Gastric cancer is one of the most common and deadly cancers. 10, 11 Several gastric cancer-related fusion genes have been reported; 9, 12 however, the impact of gene fusion in gastric cancer has not been thoroughly studied. As with the discoveries of fusion genes in other tumours, the identification of additional fusion genes in gastric cancer might provide new perspectives for its categorisation and understanding.
In the present study, we used paired end transcriptome sequencing, which is an efficient tool for detecting fusion genes. This approach allowed us to detect 23 fusion transcripts, including chimeric RNAs and fusion genes, all of which, to our knowledge, are novel. Fusion partner genes included hepatocyte growth factor receptor (MET), cyclin-dependent kinase12 (CDK12) and fibroblast growth factor receptor 2 (FGFR2) that are potential druggable targets. We also confirmed that transcriptional read-through of dihydrouridine synthase 4-like (DUS4L)-B-cell receptor-associated protein 29 (BCAP29) can be tumorigenic. Transcriptional readthrough has previously been neglected because of the lack of genetic changes that occur and has never been functionally studied. In addition, we found the plasmacytoma variant translocation 1 (Pvt-1) oncogene (PVT1), amplified and located on double minute (DM) chromosome, was involved in six different fusions. This suggests that PVT1 is associated with genetic instability resulting in gene fusions with various partners. Taken together, transcriptome sequencing provides various novel fusion transcript candidates in gastric cancer, and functional studies of these candidates contribute to enhanced understanding of gastric carcinogenesis.
RESULTS

Detection and filtration of gene fusion candidates
We sequenced the transcriptomes of 12 gastric cancer cell lines (Supplementary Table S1 ) and detected 282 gene fusion candidates (Figure 1) . From the initial list of 282 gene fusion candidates, we discarded candidates with fewer than 10 junction reads because fewer junction reads are likely indicators of false positives. In addition, we observed false positive results in about 50 candidate fusions, with less than 10 reads. After this step, only 22 candidates remained; however, we added back PVT1-ATE1, PVT1-PPAPDC1A and CD44-FGFR2 because, in terms of their loci, these three candidates were closely related to the already selected PVT1-PDHX and PVT1-APIP fusion genes. In contrast, two candidates were excluded as they are known to encode hypothetical proteins. Thus, the final list contained 23 gene fusion candidates (Figure 2 ). Apart from SNU-216, the other 11 cell lines exhibited one or more fusion transcripts.
Validation of gene fusion candidates RT-PCR and Sanger sequencing across fusion junctions were conducted to confirm 23 candidates identified by transcriptome sequencing; 19 of the 23 candidates were validated with 7 interchromosomal and 12 intra-chromosomal fusions (Table 1 and Supplementary Text S1). Five read-through fusion transcripts were among the 12 intra-chromosomal fusions. In most gene fusion studies, chimeric RNAs, which are generated by read-through/ splicing or trans-splicing, were filtered out at the beginning step because the main focus of these studies was on genetic changes. However, recent studies have suggested that RNA chimera TMEM79-SMG5 is generated by splicing in prostate cancer by deep sequencing. 8 Similarly, SLC45A3-ELK4 fusion transcript can arise from cis-splicing of adjacent genes without corresponding DNA changes, suggesting that chimeric transcript is a novel class of gene fusion. 13 On the basis of these, we included fusion transcript in our study.
In order to define genetic rearrangement status of the 19 fusion candidates, we performed long-range PCR in the genomic DNA of cancer cell lines. We confirmed that two fusion transcripts (MED1-CDK12 and CAPZA2-MET) were results of gene fusion (Supplementary Text S2) . In contrast, long-range PCR revealed that five fusion transcripts are produced by read-through mechanism (Table 1) . Although we were unable to validate genetic rearrangement in remaining 12 fusion transcripts owing to the technical limitations of long-range PCR, the 7 inter-chromosomal fusion transcripts are most likely resulting from genetic rearrangements. The genetic status of the five intra-chromosomal fusion transcripts needs to be investigated using alternative technique in future studies. In the genome, MED1 and CDK12 are neighbours, but are located on different strands with opposite orientations; therefore, MED1-CDK12 fusion can be classified as cis intra-chromosomal fusion gene. 14 CAPZA2 and MET are neighbours on the same strand. Unlike most transcriptional read-throughs, however, the genes in CAPZA2-MET fusion transcripts are in a different order from their order on the DNA strand where MET is upstream of CAPZA2, suggesting that this is not a transcriptional read-through, but a genetic fusion. Similarly, RB1-ITM2B fusion was reported in melanoma and was categorised as a fusion gene rather than a chimeric transcript. 15 Next, to investigate their relationships with tumours, we examined the expression of the fusion transcripts in 13 primary gastric cancer tissues and their matched adjacent normal mucosa (Supplementary Table S2 ). CLN6-CALML4 and DUS4L-BCAP29 were detected in 13 and 10 tumour tissues, while these are also present in 5 and 2 normal tissues, respectively. On the contrary, EIF3A-SFXN4, VAV2-CCDC67 and PVT1-ATE1 were each detected in only one tumour tissue.
Next, we used Prosite (http://prosite.expasy.org/) and SMART (http://smart.embl.de/) to predict protein translated from fusion trancripts. 16, 17 Although all the other candidate genes could encode protein products, it does not directly follow that they were all in the correct reading frame. For example, the STAG1-MSL2 fusion transcript was assumed to encode a 1289-residue protein by their sequence, but a guanine omission at the fusion junction caused a frameshift, resulting in a 786-residue protein instead. However, other fusion transcripts, for example, CAPZA2-MET, MED1-CDK12 and CD44-FGFR2, were predicted to encode protein kinase domain-containing proteins (Supplementary Text S1). The kinase domain of MED1-CDK12 is located at the fusion junction, which might be expected to alter the original CDK12 kinase, and CDK12 has been reported as a fusion partner of ERBB2 in the MKN7 cell line. 18 In contrast, the kinase domains in the CAPZA2-MET and CD44-FGFR2 proteins are not at fusion junctions; therefore, the kinase domains of MET and FGFR2 are likely to be unaffected.
Identification of novel DUS4L-BCAP29 fusion transcript An examination of transcript frequency in the cancer tissues revealed that DUS4L-BCAP29 was the most frequently detected fusion transcript (Supplementary Table S2 ). DUS4L-BCAP29 was detected and validated in the SNU-5 cell line (Figure 3a) , but no genomic level changes were detected by long-range PCR (data not shown). Considering their loci and orientation on genome, this fusion transcript is likely to be a transcriptional read-through without genetic alterations. DUS4L-BCAP29 fusion transcript was detected in 10 tumour and 2 normal tissues (Figure 3b ; left). As the normal tissues are from adjacent mucosa in the same patients, the Figure 2 . Schematic diagram of the candidate-filtering process. To increase the validation rate, candidates with fewer than 10 junction reads were discarded. Candidates predicted to encode not-fully validated/reviewed protein were also removed, leaving 23 final candidate fusion genes. Novel fusion transcripts in gastric cancer H-P Kim et al two normal samples harboring the fusion transcripts could be the result of field effects. The expression of DUS4L-BCAP29 fusion transcript was higher than its normal counterpart (Figure 3b ; right). To study its biologic function, SNU-5 cells were treated with small interfering RNA (siRNA) to silence the expression of DUS4L-BCAP29 transcript. Si-DUS4L-BCAP29 repressed the expression of the fusion transcripts effectively, but hardly affected the expression of wild-type DUS4L, indicating that si-DUS4L-BCAP29 specifically silenced the fusion transcript ( Figure 3c ). Treatment with si-DUS4L-BCAP29 significantly suppressed the proliferation of SNU-5 cells compared with treatment with the si-control ( Figure 3d ). In contrast, siRNA specifically targeting DUS4L but not the fusion transcript did not affect cell proliferation (data not shown). Taken together, it is the fusion transcript DUS4L-BCAP29 that is promoting cell proliferation but not DUS4L itself. Treatment with si-DUS4L-BCAP29 reduced the expression of AKT, ERK and their phosphorylated forms (Supplementary Figure S1) . It was also found that the expression of cyclin D was repressed in si-DUS4L-BCAP29-treated cells. Cell cycle analysis showed that cells in G 1 and subG 1 were increased in DUS4L-BCAP29-silenced cells. Western blot showed evidence of apoptosis revealed by the cleavage of PARP, caspase-7 and caspase-3 and the downregulation of Bcl-2 and Bcl-XL and upregulation of Bim in DUS4L-BCAP29-silenced cells compared with the controls (Supplementary Figure S2) . To confirm the potential tumorigenic effect of DUS4L-BCAP29 transcript, SNU-638 cell line not expressing the fusion transcript was transfected with mock or DUS4L-BCAP29 and was investigated for anchorage-independent growth. After 14-day culture in soft agar, DUS4L-BCAP29-expressing cells clearly formed more foci, compared with control cells (Figure 3e) . We also examined cell proliferation after overexpressing DUS4L-BCAP29 in SNU-638 cell line. Proliferation was increased in a time-dependent manner in DUS4L-BCAP29-overexpressed SNU-638 cells but not in control cells (Figure 3f ). We also observed that the expressions of cyclin D and E increased. These results were confirmed using BrdU incorporation assay (Figure 3g ). The series of experiments we have performed strongly suggest that the novel DUS4L-BCAP29 fusion transcript is tumorigenic in gastric cancer.
PVT1: a tangled web of gene fusion We found complicated genetic alterations in SNU-16 cells, around PVT1 located on chromosome 8q24. PVT1 was involved in four different fusion genes including, PVT1-PDHX, PVT1-APIP, PVT1-ATE1 and PVT1-PPAPDC1A (Figure 4a ). It was the most frequent fusion partner we observed in a single cell line. Interestingly, all the validated PVT1-associated fusions were inter-chromosomal. APIP and PDHX are neighbouring genes on chromosome 11; PPAPDC1A and ATE1 are close to each other on chromosome 10; CD44 is a neighbour of PDHX; and FGFR2 is located between PPAPDC1A and ATE1. Because of their proximities, we returned PVT1-ATE1, PVT1-PPAPDC1A and CD44-FGFR2 to the candidate list for validation by RT-PCR and Sanger sequencing. With one exception, PDHX exon3-PVT1 exon4, all of these gene fusion had PVT1 exon1 just before the fusion junctions (Figure 4b ). Recently reported PVT1-associated fusions, PVT1-NBEA and PVT1-WWOX in multiple myeloma, also have PVT1 exon1 at the fusion junctions. 19 Break points near PVT1 were also detected frequently in multiple myeloma patients and in cell lines. 19 We performed array CGH to identify genetic changes in the joining regions (Figure 4c) . The PVT1 copy-number showed abrupt changes within the gene itself, implying the presence of genomic breaks. The copy-numbers of its partner genes also did not seem stable (log 2 ratio ¼ 1). The regions covering APIP to CD44 and FGFR2 were amplified, and ATE1 showed two sudden changes in copy-number, indicating genomic break points. These findings support the susceptibility of PVT1 to genomic break, in agreement with previous studies. 19 Fluorescence in situ hybridisation (FISH) added more evidence of PVT1 breakage in SNU-16 cells (Figure 4d ). Multiple extrachromosomal double minute chromosomes on which PVT1 was highly amplified have been reported in SNU-16 cells. 20 In contrast, DNA obtained from the tissue of a normal male showed only one PVT1 pair on chromosome 8. Although most amplified PVT1 genes were not broken apart, some exhibited only one probe colour (red or green), indicating that the chromosome was unpaired and had broken apart (Figure 4d ). Therefore, gene amplification of PVT1 and its breakage seem to be responsible for most of the tangled gene fusion web found in SNU-16.
DISCUSSION
From the initial 282 gene fusion candidates, we obtained 23 candidates after filtering using our criteria for a higher validation rate (Figure 2 ). Of the 23 candidates, 19 were validated using RT-PCR and Sanger sequencing (Table 1 ; Supplementary Text S1). Seven were classified as inter-chromosomal fusions and 12 were classified as intra-chromosomal fusions. The 12 intra-chromosomal fusions included five read-through candidates. In the present study, read-through transcript was defined when any genetic change was not identified by long-range PCR. However, negative result from long-range PCR may not completely exclude the possibility of genetic rearrangement. In the present study, 19 fusion candidates were categorised into three groups by their frequencies in tissue samples and their component genes. The first group contains two fusion transcripts that were common in the tumour tissues, namely, DUS4L-BCAP29 and CLN6-CALML4, which, because of their adjacent genomic loci and lack of genomic PCR products, were categorised as readthrough transcripts. Although they were detected in a few normal tissues, they were much more common in tumour tissues. DUS4L-BCAP29 and CLN6(exon2)-CALML4(exon4) were detected in 76.9% and 46.2% of the tumour tissue sample, respectively (Supplementary Table S2 ). CLN6-CALML4 had three variants, and all were commonly expressed in tumour tissues. The functions of read-through fusion transcripts without genetic alteration remain relatively understudied. Mechanisms of their formation and their recurrence in cancer tissues have been reported, 8, 13, 21, 22 but their specific functions and contributions to cancer have not been studied in depth. Here, we have shown that DUS4L-BCAP29 contributes to cell proliferation via antiapoptosis signalling ( Figure 3 ). Further studies are planned to elucidate the mechanism by which DUS4L-BCAP29 are generated. We also found that three candidates show tumour-specific expression, EIF3A-SFXN4, VAV2-CCDC67 and PVT1-ATE1, but detected in only in one tumour each.
Second group contains oncogenes for which drugs exist, namely, CAPZA2-MET, MED1-CDK12 and CD44-FGFR2. Currently, various MET, CDK and FGFR inhibitors are being developed and under clinical trials. 23, 24 The CAPZA2-MET fusion transcript was detected in MKN45 cells containing amplified MET. Abnormal MET signalling is a well-known marker of poor prognosis and drug resistance, and, as a result, MET has been studied intensively as an anticancer drug target. 25 MKN45 cells containing amplified MET and CAPZA2-MET fusion are sensitive to MET inhibitors. 26 Considering that MET is amplified in MKN45 cells, 27 it is possible that regional gene amplification of MET might have generated the CAPZA2-MET fusion. MET-specific antibodies might be less sensitive than tyrosine kinase inhibitors for this protein because it has lost a large part of its extracellular domain. In contrast, CDK12 has not been a mainstream target of anticancer drugs, including the CDK inhibitors. The MED1-CDK12 fusion gene is predicted to alter the protein kinase domain of CDK12 (Supplementary Text S1). The biological consequence of the altered protein kinase needs to be elucidated in the future. FGFR2 is another anticancer drug target for which several drugs have been already developed. 28 We confirmed CD44-FGFR2 in an SNU-16 cell line (Supplementary Text S1). SNU-16 cells containing amplified FGFR2 and CD44-FGFR2 fusion are sensitive to FGFR inhibitor. 29 Third group contains four gene fusions and their variants that were detected in SNU-16 cell lines and that have PVT1 as a component gene (Figure 4) . PVT1 exon1 is known to encode the oncogenic microRNA miR1204 30 and, because the microRNAcoding gene PVT1 is located at the head of the fusion, further studies should define the functional results of these fusions. Most of the amplified PVT1 was located on double minute chromosomes (Figure 4d ). The amplified FGFR2 in SNU-16 also resides on double minute chromosomes. 20 Considering that the amplified PVT1 and FGFR2 in SNU-16 exist on double minute chromosomes, and their involvement in gene fusion, these genes could mutate and fuse with each other during amplification events or during the generation of double minute chromosomes. The suggestion that double minute chromosomes are associated with fusion genes is supported by a previous finding that NUP214-ABL1 fusion was amplified and detected in a double minute chromosome from a T-cell acute lymphoblastic leukaemia. 31 Moreover, it is plausible that the tangled web of gene fusion is related with chromothripsis, in that localised blocks of chromosomes are rearranged. 32 Future studies elucidating the relationships between the gene fusion, double minute chromosome and chromothripsis are warranted.
In summary, we describe here several novel gene fusion events in gastric cancer revealed by next-generation transcriptome sequencing. It is notable that transcriptional read-through without DNA rearrangement could be another mechanism of tumorigenesis. We also found that an amplified gene in a double minute chromosome could be a source of various gene fusions with different partners.
MATERIALS AND METHODS
Cell lines and culture
Human gastric adenocarcinoma cell lines (SNU-1, SNU-5, SNU-16, SNU-216, SNU-484, SNU-601, SNU-620, SNU-638, SNU-668 and SNU-719) were purchased from the Korean Cell Line Bank; 20 the NCI-N87 and MKN45 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) and Health Science Research Resource Bank (Osaka, Japan), respectively. All cell lines were cultured in RPMI1640 (Hyclone Laboratories, Ind., Logan, UT, USA), supplemented with 10% fetal bovine serum at 37 1C in a 5% CO 2 -humidified atmosphere.
Paired-end transcriptome sequencing
Complementary DNA (cDNA) samples were sequenced using a Genome Analyzer IIx (Illumina Inc., San Diego, CA, USA). For the mRNA-Seq sample preparation, sequencing libraries were generated according to the standard Illumina protocol for high-throughput sequencing. We hybridised 8 pM of each library to a flow cell, with a single lane for each sample, and used an Illumina cluster station for cluster generation. Finally, we generated 2 Â 53 bp and 1 Â 38 bp sequences using Illumina GAIIx (Illumina Inc) sequencer (Supplementary Table S1 ).
Alignment of sequenced reads. We used the standard Illumina pipeline (cassava 1.6) with default options to analyse the images and extract base calls. The sequenced reads were aligned using GSNAP, 33 with the nondefault parameters -m 3 INSERT SIZE:-p 300 -i 3, and allowing up to two mismatches with the reference sequences. The sequenced reads were aligned to human transcript reference sequences from the UCSC database (Homo_sapiens.GRCh36), and to the human genome sequence (NCBI Build 36.3) and known exon-exon junctions, for expression analysis at the gene/ transcript levels. Discordant read pairs and fusion-spanning reads were extracted from the mapping results and used to identify gene fusion events. The pipeline that we used to detect fusion genes has been described previously. 34, 35 Filtration steps. (1) Homology between two genes was detected using bl2seq (BLAST 2 sequences); similar genes were filtered out (E-value o0.01). (2) Fusion-spanning reads mapped by fewer than 10 bp to either gene in the fusion were discarded. Somatic gene fusions were obtained by removing the gene fusions that were also observed in the normal sample.
RT-PCR and quantitative real-time RT-PCR. Total RNA was extracted from the each cell line using an RNeasy mini kit (Qiagen, Valencia, CA, USA) for transcriptome sequencing following the manufacturer's instructions. cDNA was synthesised from total RNA (1 mg) with ImProm-II reverse transcriptase (Promega, Madison, WI, USA) and amplified by RT-PCR using AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City, CA, USA) with buffer supplied by the manufacturer with gene/fusion junction-specific primers. The primers were synthesised by Macrogen Inc. (Seoul, Korea). b-Actin expression was used as an internal RT-PCR control. Sequencing was carried out by Macrogen Inc. and Bionics Co., Ltd (Seoul, Korea). For quantitative real-time RT-PCR (qRT-PCR), cDNA was amplified using Premix Ex Taq (TaKaRa, Shiga, Japan) with SYBR Green I (Molecular Probes, Eugene, OR, USA) using a Step One Plus system (Applied Biosystems). The sequences of all the PCR primers used in this study are listed in Supplementary Table S3 .
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Primary human gastric tissues
Thirteen human gastric tumour tissues and the matched normal tissues were obtained from the tissue bank of Seoul National University Hospital (Seoul, Korea). After surgical removal, the tissues were immediately frozen in liquid nitrogen and stored until required.
siRNAs and transfection
The siRNAs, including the control siRNA (si-CONTROL) with scrambled sequences, used in this study were synthesised by Genolution Pharmaceuticals, Inc. (Seoul, Korea). The siRNA sequences used against the DUS4L-BCAP29 fusion transcript were 5 0 -GAAACAUAUCUGUAUUAAUUU-3 0 (sense) and 5
0 -AUUAAUACAGAUAUGUUUCUU-3 0 (antisense). Each siRNA (50 nM) was treated in each cell line, twice separately, with an interval of 48 h. Transfection was performed with Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instruction.
Cell proliferation assay
Immediately after the second treatment with si-DUS4L-BCAP29 or its control, the cells were plated in complete growth media in 60 mm dishes (7 Â 10 5 cells per dish). From the next day and for 3 days, the number of total cells in each dish was counted. Three independent experiments were performed.
DUS4L-BCAP29 Cloning
Human DUS4L-BCAP29 from a cDNA pool of SNU-16 cells was amplified and cloned into diverse mammalian expression vectors by using PCR methods. Forward primer was 5 0 -CCGCTCGAGCTAAGCTTATGAAGAGT-GACTGCATGCAAACGACAATA-3 0 and reverse primer was 5 0 -CGGAATT-CAAGCTTTCACAGTCTTTTCTTGTTG CCTCTTTCTAA -3 0 . The cDNA was inserted into XhoI/EcoRI cloning sites of pEGFP-C1 (pEGFP-DUS4L-BCAP29).
BrdU incorporation and cell growth analysis
BrdU incorporation analysis of confluent cells under different experimental conditions and cell growth analysis by viable cell counting were performed as described previously. 17 Soft agar assay Cells without or with DUS4L-BCAP29 expression were processed for soft agar assay as described previously. 19 The plates were then incubated for 14 days in a 5% CO 2 incubator at 37 1C, with replenishment of medium containing 200 mg/ml G418 and 10% FBS every other day. Colonies were imaged using a digital camera-equipped microscope.
Cell cycle analysis
After incubation with the second treatment of siRNAs for 24 h, the cells were centrifuged at 1500 r.p.m. for 5 min, fixed in 70% alcohol and stored at À 20 1C. Ten microliters of RNAse (100 mg/ml) was added to the samples; subsequently, the samples were incubated at 37 1C for 10 min and then treated with propidium iodide, after which the DNA content of the cells (10 000 cells per experimental group) was determined using an FACSCalibur flow cytometer (Becton Dickinson Biosciences, San Jose, CA, USA) with a ModFit LT program (Verity Software House, Inc., Topsham, ME, USA).
Western blotting and antibodies
Cultured cells were washed with ice-cold phosphate-buffered saline and lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 0.1% sodium deoxycholate, 150 mM NaCl, 50 mM NaF, 1 mM sodium pyrophosphate, 1 mM EDTA and protease/phosphatase inhibitors). Twenty micrograms of total protein was resolved using SDS-PAGE. The resolved proteins were then transferred to nitrocellulose membranes. After blocking with 1% skim milk and 1% BSA/Tris-buffered saline with Tween 20 (TBST), the membranes were incubated with primary antibodies at 4 1C overnight. Antibodies against cyclin D, p-AKT (pS-473), AKT, p-ERK (p44/42), ERK, PARP, caspase-7, caspase-3, Bcl-2 and Bim were purchased from Cell Signaling Technology (Beverley, MA, USA). Antibodies against cyclin E, actin and Bcl-XL were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). An anti-a-tubulin antibody was acquired from Sigma-Aldrich (St Louis, MO, USA).
Array Comparative Genomic Hybridisation (array CGH) analysis
Genomic DNA from cells was analysed using array CGH using a 2 Â 400 K oligonucleotide microarray (Agilent Technologies, Santa Clara, CA, USA) according to the manufacturer's recommendations. The test DNA (2 mg) and reference DNA (2 mg) were digested with AluI and RsaI (Promega). The digested test and reference DNAs were labelled with cyanine (Cy)3-deoxyuridine triphosphate (dUTP) or Cy5-dUTP, respectively, using the Agilent Genomic DNA Labeling Kit PLUS (Agilent). The individually labelled test and reference samples were then purified using Microcon YM-30 filters (Millipore, Billerica, MA, USA). Following purification, the appropriate Cy3-labelled test DNA and Cy5-labelled reference DNA were mixed together and combined with 2 Â hybridisation buffer (Agilent), 10 Â blocking agent (Agilent) and human Cot-1 DNA (Invitrogen). The hybridisation mixture was dispensed slowly to a microarray chip and assembled with an Agilent SureHyb chamber. The assembled slide chamber was placed in the rotator rack in a hybridisation oven set to 65 1C for 40 h with suitable rotation. The hybridisation was followed by two washing steps in Agilent's wash buffer 1 and wash buffer 2 following the manufacturer's instructions. After washing, all microarray slides were scanned on an Agilent Microarray Scanner G2505C with a 5-mm resolution. Captured images were transformed to data with Feature Extraction Software, version 10.7 (Agilent) and then imported into Agilent CGH Analytics 5.0.14 software for analysis.
Data analysis
The analysis and visualisation of the array CGH-2 Â 400 K data were performed using Agilent CGH Analytics 5.0.14 software. A comprehensive description of the statistical algorithms is available in the user's manual provided by Agilent Technologies. In brief, the Aberration Detection Method 2 quality-weighted interval score algorithm identifies aberrant intervals in samples that have consistently high or low log ratios, based on their statistical score. The score represents the deviation of the weighted average of normalised log ratios from its expected value of zero calculated with Derivative Log2 Ratio Standard Deviation algorithm. A Fuzzy Zero algorithm is applied to incorporate quality information about each probe measurement. The threshold settings that we used for the CGH analytics software to make a positive call were 6.0 for sensitivity, 0.25 for minimum absolute average log ratio per region and 3 consecutive probes with the same polarity for the minimum number of probes per region.
Fluorescence in situ hybridisation FISH and its analysis were carried out by Macrogen Inc. with specific BAC clones, which were also from Macrogen Inc. The probes were labelled with two different fluorochromes, FITC (green) and Cy3 (red). Detailed probe information is given in Supplementary Table S4. 
